Mallinckrodt

Mallinckrodt to acquire Stratatech

Monday, August 15, 2016

Mallinckrodt, a global specialty pharmaceutical company, has entered into a merger agreement with Stratatech, a privately held regenerative medicine company focused on the development of unique, proprietary skin substitute products. Developmental products include StrataGraft regenerative skin tissue and a technology platform for genetically enhanced skin tissues. Financial terms of the transaction were not disclosed.

[Read More]

Mallinckrodt Pharmaceuticals acquires Therakos

Wednesday, August 12, 2015

Mallinckrodt, a Dublin-based global specialty biopharmaceutical company, and The Gores Group, a global investment firm, have entered into a definitive agreement under which a subsidiary of Mallinckrodt will acquire Therakos, a West Chester, Pa.-based immunotherapy company, for about $1.3 billion. Subject to customary closing conditions, the transaction will close by the end of 2015.

[Read More]